COPD, or chronic obstructive pulmonary disease, is a group of life-changing lung diseases that include emphysema and chronic bronchitis. 1 Those living with COPD can experience coughing, wheezing, ...
Napa, CA (October 24, 2007) – Data from two Phase III clinical trials were presented today in Chicago at CHEST 2007, the annual scientific assembly of the American College of Chest Physicians (ACCP), ...
Chronic obstructive pulmonary disease (COPD) is among the most common lung diseases in the world. According to the World Health Organization, the lung disease is the fourth leading cause of death ...
After 12 weeks of nebulized NAC, patients’ mean phlegm scores, as measured by the COPD assessment test, significantly decreased from 3.47 at baseline to 2.62. N-acetylcysteine (NAC) nebulizer therapy ...
Napa, CA (May 20, 2008) – Data presented today at the International Conference of the American Thoracic Society (ATS) demonstrate that Perforomist™ Inhalation Solution (formoterol fumarate inhalation ...
Ohtuvayre (ensifentrine), a drug approved in 2024 to treat chronic obstructive pulmonary disorder (COPD), is receiving high marks from doctors and patients. Ohtuvayre is the first new inhaled COPD ...
COPD, or chronic obstructive pulmonary disease, is a group of life-changing lung diseases that include emphysema and chronic bronchitis. 1 Those living with COPD can experience coughing, wheezing, ...
For individuals living with COPD, small changes may make a difference. Byline: Viatris Inc. and Theravance Biopharma US, Inc. COPD, or chronic obstructive pulmonary disease, is a group of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results